A new study offers insights into how the gene neuropilin2 contributes to the development of behavioral changes associated with autism spectrum disorder and epilepsy.
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...